表 7. Global research hotspots on oncology: bone and soft tissues, hepatology, skin and body surface.
肿瘤领域全球研究热点——骨与软组织肿瘤、血液肿瘤、皮肤体表肿瘤
| 研究主题 | 相关研究 | 被引次数
查询时间 2020.09.23 |
期刊来源 |
| 骨与软组织肿瘤 | |||
| 临床试验 | Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma（SARC028）：a multicentre，two-cohort，single-arm，open-label，phase 2 trial[66] | 233 | Lancet Oncol |
| Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial：data from the HORRAD trial[67] | 100 | Eur Urol | |
| 血液肿瘤 | |||
| 临床试验 | Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma[68] | 258 | J Clin Oncol |
| Early positron emission tomography response-adapted treatment in stage I and II hodgkin lymphoma：final results of the randomized EORTC/LYSA/FIL H10 trial[69] | 158 | J Clin Oncol | |
| Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia：a non-randomised，open-label，phase 1b study[70] | 213 | Lancet Oncol | |
| Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia[71] | 247 | N Engl J Med | |
| Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic hodgkin lymphoma[72] | 404 | J Clin Oncol | |
| 测序 | Molecular minimal residual disease in acute myeloid leukemia[73] | 212 | N Engl J Med |
| Prediction of acute myeloid leukaemia risk in healthy individuals[74] | 159 | Nature | |
| CAR-T | T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma[75] | 169 | J Clin Oncol |
| 皮肤体表肿瘤 | |||
| 黑色素瘤 | Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab[76] | 297 | Ann Oncol |
| Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events：a pooled analysis of randomized phase II and III trials[77] | 153 | J Clin Oncol | |
| Randomized，open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced，unresectable melanoma[78] | 160 | J Clin Oncol | |
| Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma（COLUMBUS）：a multicentre，open-label，randomised phase 3 trial[79] | 198 | Lancet Oncol | |
| Pembrolizumab versus ipilimumab for advanced melanoma：final overall survival results of a multicentre，randomised，open-label phase 3 study（KEYNOTE-006）[80] | 419 | Lancet | |
| 皮肤鳞状细胞癌 | PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma[81] | 271 | N Engl J Med |